Lazard Asset Management LLC Raises Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Lazard Asset Management LLC grew its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating) by 121.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 26,919 shares of the biopharmaceutical company’s stock after buying an additional 14,751 shares during the quarter. Lazard Asset Management LLC’s holdings in Sangamo Therapeutics were worth $111,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in SGMO. Penserra Capital Management LLC purchased a new position in shares of Sangamo Therapeutics during the first quarter worth about $66,000. Brown Advisory Inc. grew its holdings in shares of Sangamo Therapeutics by 49.0% during the second quarter. Brown Advisory Inc. now owns 18,779 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 6,176 shares during the last quarter. AlphaCrest Capital Management LLC grew its holdings in shares of Sangamo Therapeutics by 25.4% during the first quarter. AlphaCrest Capital Management LLC now owns 14,419 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 2,919 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Sangamo Therapeutics during the first quarter worth about $94,000. Finally, Delphia USA Inc. grew its holdings in shares of Sangamo Therapeutics by 44.5% during the first quarter. Delphia USA Inc. now owns 20,983 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 6,457 shares during the last quarter. Hedge funds and other institutional investors own 57.53% of the company’s stock.

Insider Buying and Selling at Sangamo Therapeutics

In other Sangamo Therapeutics news, major shareholder Biogen Inc. sold 400,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $5.33, for a total value of $2,132,000.00. Following the sale, the insider now owns 23,752,466 shares of the company’s stock, valued at approximately $126,600,643.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. StockNews.com lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 2nd. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $22.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $12.50.

Sangamo Therapeutics Price Performance

NASDAQ SGMO opened at $3.60 on Wednesday. Sangamo Therapeutics, Inc. has a 52-week low of $3.12 and a 52-week high of $9.02. The business’s 50-day moving average price is $4.50 and its 200 day moving average price is $4.54. The firm has a market cap of $589.97 million, a P/E ratio of -3.03 and a beta of 1.22.

Sangamo Therapeutics Profile

(Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Recommended Stories

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.